13.2 USD
-0.2 (-1.49%)
13.06 USD
-0.14 (-1.06%)
Taking everything into account, HCM scores 5 out of 10 in our fundamental rating. HCM was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of HCM get a neutral evaluation. Nothing too spectacular is happening here. HCM is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year HCM was profitable.
HCM had a negative operating cash flow in the past year.
In multiple years HCM reported negative net income over the last 5 years.
In multiple years HCM reported negative operating cash flow during the last 5 years.
1.2 Ratios
HCM has a Return On Assets of 26.29%. This is amongst the best in the industry. HCM outperforms 98.95% of its industry peers.
Looking at the Return On Equity, with a value of 37.99%, HCM belongs to the top of the industry, outperforming 96.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.29% | ||
| ROE | 37.99% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HCM has a better Profit Margin (77.53%) than 98.95% of its industry peers.
HCM's Gross Margin of 44.15% is fine compared to the rest of the industry. HCM outperforms 62.83% of its industry peers.
In the last couple of years the Gross Margin of HCM has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 77.53% | ||
| GM | 44.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.54%
GM growth 5Y15.38%
2. Health
2.1 Basic Checks
HCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for HCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
HCM has an Altman-Z score of 3.34. This indicates that HCM is financially healthy and has little risk of bankruptcy at the moment.
HCM has a Altman-Z score of 3.34. This is in the better half of the industry: HCM outperforms 68.06% of its industry peers.
HCM has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.08, HCM is in line with its industry, outperforming 51.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.34 |
ROIC/WACCN/A
WACC9.3%
2.3 Liquidity
A Current Ratio of 4.65 indicates that HCM has no problem at all paying its short term obligations.
HCM has a better Current ratio (4.65) than 63.35% of its industry peers.
HCM has a Quick Ratio of 4.51. This indicates that HCM is financially healthy and has no problem in meeting its short term obligations.
HCM has a Quick ratio of 4.51. This is in the better half of the industry: HCM outperforms 64.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.51 |
3. Growth
3.1 Past
HCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1172.34%, which is quite impressive.
The Revenue has decreased by -1.41% in the past year.
HCM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.20% yearly.
EPS 1Y (TTM)1172.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1661.49%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y20.96%
Revenue growth 5Y25.2%
Sales Q2Q%-9.16%
3.2 Future
The Earnings Per Share is expected to grow by 52.63% on average over the next years. This is a very strong growth
Based on estimates for the next years, HCM will show a very strong growth in Revenue. The Revenue will grow by 20.25% on average per year.
EPS Next Y900.61%
EPS Next 2Y81.46%
EPS Next 3Y57.47%
EPS Next 5Y52.63%
Revenue Next Year-11.82%
Revenue Next 2Y0.94%
Revenue Next 3Y5.99%
Revenue Next 5Y20.25%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
HCM is valuated cheaply with a Price/Earnings ratio of 4.85.
Based on the Price/Earnings ratio, HCM is valued cheaply inside the industry as 96.34% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.77. HCM is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 31.54 indicates a quite expensive valuation of HCM.
71.73% of the companies in the same industry are more expensive than HCM, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.35. HCM is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.85 | ||
| Fwd PE | 31.54 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HCM's earnings are expected to grow with 57.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y81.46%
EPS Next 3Y57.47%
5. Dividend
5.1 Amount
No dividends for HCM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
13.2
-0.2 (-1.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners18.88%
Inst Owner Change-5.06%
Ins Owners0.58%
Ins Owner ChangeN/A
Market Cap2.27B
Revenue(TTM)602.20M
Net Income(TTM)466.88M
Analysts83.7
Price Target15.41 (16.74%)
Short Float %0.4%
Short Ratio12.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.07%
PT rev (3m)-11.46%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.04%
EPS NY rev (3m)-0.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-4.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.85 | ||
| Fwd PE | 31.54 | ||
| P/S | 3.77 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.85 | ||
| P/tB | 1.85 | ||
| EV/EBITDA | N/A |
EPS(TTM)2.72
EY20.61%
EPS(NY)0.42
Fwd EY3.17%
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS3.5
BVpS7.15
TBVpS7.15
PEG (NY)0.01
PEG (5Y)N/A
Graham Number20.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.29% | ||
| ROE | 37.99% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 77.53% | ||
| GM | 44.15% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.54%
GM growth 5Y15.38%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 221.94% | ||
| Cap/Sales | 4.5% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.51 | ||
| Altman-Z | 3.34 |
F-Score5
WACC9.3%
ROIC/WACCN/A
Cap/Depr(3y)321.95%
Cap/Depr(5y)304.39%
Cap/Sales(3y)5.11%
Cap/Sales(5y)5.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1172.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1661.49%
EPS Next Y900.61%
EPS Next 2Y81.46%
EPS Next 3Y57.47%
EPS Next 5Y52.63%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y20.96%
Revenue growth 5Y25.2%
Sales Q2Q%-9.16%
Revenue Next Year-11.82%
Revenue Next 2Y0.94%
Revenue Next 3Y5.99%
Revenue Next 5Y20.25%
EBIT growth 1Y83.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.15%
EBIT Next 3Y46.12%
EBIT Next 5Y43.18%
FCF growth 1Y-2591.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.32%
OCF growth 3YN/A
OCF growth 5YN/A
HUTCHMED CHINA-ADR / HCM FAQ
Can you provide the ChartMill fundamental rating for HUTCHMED CHINA-ADR?
ChartMill assigns a fundamental rating of 5 / 10 to HCM.
What is the valuation status of HUTCHMED CHINA-ADR (HCM) stock?
ChartMill assigns a valuation rating of 5 / 10 to HUTCHMED CHINA-ADR (HCM). This can be considered as Fairly Valued.
Can you provide the profitability details for HUTCHMED CHINA-ADR?
HUTCHMED CHINA-ADR (HCM) has a profitability rating of 4 / 10.
Can you provide the financial health for HCM stock?
The financial health rating of HUTCHMED CHINA-ADR (HCM) is 5 / 10.